Ultimovacs ASA (ULTI.OL)
NOK 2.05
(0.0%)
NOK 2.05
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -214.85 Million NOK | -15.49% |
| 2022 | -164.9 Million NOK | -16.53% |
| 2021 | -161.68 Million NOK | -31.48% |
| 2020 | -117.59 Million NOK | -89.27% |
| 2019 | -58.84 Million NOK | -14.72% |
| 2018 | -55.92 Million NOK | -70.2% |
| 2017 | -32.85 Million NOK | -14.5% |
| 2016 | -28.69 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -27.93 Million NOK | 63.23% |
| 2024 Q2 | -45.12 Million NOK | -102.02% |
| 2023 Q1 | -32.87 Million NOK | 62.18% |
| 2023 Q4 | -67 Million NOK | -34.6% |
| 2023 Q3 | -49.78 Million NOK | -19.6% |
| 2023 Q2 | -41.62 Million NOK | -26.6% |
| 2023 FY | - NOK | -19.96% |
| 2022 Q2 | -21.11 Million NOK | 29.73% |
| 2022 Q1 | -30.04 Million NOK | 48.64% |
| 2022 FY | - NOK | -16.53% |
| 2022 Q4 | -86.92 Million NOK | -133.54% |
| 2022 Q3 | -37.21 Million NOK | -76.29% |
| 2021 Q1 | -29.49 Million NOK | -2.38% |
| 2021 FY | - NOK | -31.48% |
| 2021 Q4 | -58.5 Million NOK | -52.99% |
| 2021 Q2 | -34.89 Million NOK | -18.29% |
| 2021 Q3 | -38.23 Million NOK | -9.59% |
| 2020 Q4 | -28.81 Million NOK | 1.77% |
| 2020 Q1 | -29.15 Million NOK | 2.69% |
| 2020 Q2 | -34.12 Million NOK | -17.06% |
| 2020 Q3 | -29.33 Million NOK | 14.06% |
| 2020 FY | - NOK | -89.27% |
| 2019 Q1 | -14.22 Million NOK | -2.43% |
| 2019 FY | - NOK | -14.72% |
| 2019 Q4 | -29.96 Million NOK | -80.1% |
| 2019 Q3 | -16.63 Million NOK | -398.83% |
| 2019 Q2 | -3.33 Million NOK | 76.55% |
| 2018 Q1 | -10.77 Million NOK | -33.6% |
| 2018 FY | - NOK | -70.2% |
| 2018 Q4 | -13.88 Million NOK | 16.73% |
| 2018 Q3 | -16.67 Million NOK | -14.24% |
| 2018 Q2 | -14.59 Million NOK | -35.5% |
| 2017 Q1 | -8.67 Million NOK | 0.0% |
| 2017 Q2 | -7.83 Million NOK | 9.72% |
| 2017 Q4 | -8.06 Million NOK | 2.68% |
| 2017 Q3 | -8.28 Million NOK | -5.76% |
| 2017 FY | - NOK | -14.5% |
| 2016 FY | - NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arctic Bioscience AS | -37.78 Million NOK | -468.619% |
| Aqua Bio Technology ASA | -16.56 Million NOK | -1196.821% |
| ArcticZymes Technologies ASA | 31.64 Million NOK | 778.96% |
| BerGenBio ASA | -191.8 Million NOK | -12.018% |
| Hofseth BioCare ASA | -70.6 Million NOK | -204.311% |
| PCI Biotech Holding ASA | -22.22 Million NOK | -866.835% |
| Thor Medical ASA | -6.82 Million NOK | -3046.141% |